Dual SORT LNPs Enable Multi-Organ Base Editing

In a groundbreaking advancement poised to revolutionize therapeutic approaches for genetic diseases affecting multiple organs, researchers have unveiled a novel lipid nanoparticle delivery system that achieves precise base editing simultaneously in both the liver and the lungs. This innovative strategy holds remarkable promise for treating Alpha-1 antitrypsin deficiency (AATD), a hereditary condition caused by mutations in the SERPINA1 gene. AATD critically impacts two vital organs: the liver, where the accumulation of misfolded alpha-1 antitrypsin (A1AT) proteins leads to cellular damage and hepatic dysfunction, and the lungs, where insufficient A1AT levels result in unchecked neutrophil elastase activity and consequent emphysema.

The disease’s complexity stems from the contrasting yet intertwined pathological processes in these organs. In the liver, the mutant PiZ allele of SERPINA1 causes the production of aberrant A1AT proteins that misfold and aggregate within hepatocytes, leading to hepatic stress, inflammation, and ultimately fibrosis or cirrhosis. Meanwhile, the lungs suffer from A1AT deficiency, which impairs the inhibition of proteolytic enzymes like neutrophil elastase, resulting in progressive alveolar damage and emphysema. Conventional therapies have been limited to either symptomatic management or interventions targeting one organ at a time, owing largely to the challenge of delivering genetic medicines effectively to multiple tissues.

Enter the domain of base editing—a precise genetic engineering tool capable of converting individual nucleotides in the genome without inducing double-stranded DNA breaks. Although base editing offers a curative potential for diseases such as AATD, translating these molecular tools from the laboratory bench to systemic therapy has been hampered by delivery obstacles. Lipid nanoparticles (LNPs) have emerged as a versatile platform for RNA and gene editing payload delivery, but achieving simultaneous, selective targeting of disparate organs like the liver and lungs has remained elusive.

.adsslot_BSjoWYHtOu{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_BSjoWYHtOu{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_BSjoWYHtOu{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

The team led by Kim, Song, and Chen has pushed the boundaries of nanoparticle engineering to develop Dual Selective Organ-Targeting lipid nanoparticles, or Dual SORT LNPs, a pioneering technology that enables efficient co-delivery of base editors to hepatocytes and alveolar type II (AT2) cells in the lungs. This system leverages sophisticated modifications in LNP composition and physicochemical properties to navigate differential tissue tropism post-intravenous administration, a feat previously unattainable with monofunctional nanoparticles.

Utilizing the Dual SORT LNPs, the researchers demonstrated an impressive 40% base correction efficiency in liver cells harboring the PiZ mutation. This level of editing is substantial, given the genetic heterogeneity and challenges associated with in vivo gene modification. Notably, the pulmonary component was equally remarkable, with approximately 10% editing observed in lung AT2 cells. AT2 cells, responsible for surfactant production and alveolar homeostasis, are pivotal in the lung pathology of AATD, and this editing efficiency stands as a significant benchmark in pulmonary gene therapy.

Beyond initial editing, the durability and functional impact of the corrections were profound. In the liver, the base editing persisted consistently over a 32-week observation period, indicating stable genomic modification rather than transient RNA editing effects. This durability translated to a dramatic reduction—over 80%—in serum levels of the pathological Z-allele A1AT protein variant, effectively normalizing the hepatic phenotype and mitigating the risk of progressive liver disease. Such sustained effects are critical for chronic conditions like AATD, where lifelong protein misfolding and tissue damage occur.

Parallel to hepatic benefits, the therapeutic impact in the lungs was validated by biochemical assays showing an 89% inhibition of neutrophil elastase activity in bronchoalveolar lavage fluid. This restoration of protease-antiprotease balance offers direct evidence of alleviating pulmonary damage pathways and implies a reduction in lung inflammation and emphysema progression. These findings suggest that Dual SORT LNPs confer not just molecular correction but meaningful physiological and clinical improvements.

At a mechanistic level, the study elucidated how the intricate lipid formulations enable selectivity. By tuning the ionizable lipid components and incorporating organ-specific targeting moieties, the nanoparticles achieve preferential uptake and endosomal escape within distinct cellular microenvironments of the liver and lung. This precision circumvents off-target distribution and mitigates systemic toxicity, addressing a key limitation of earlier gene editing delivery platforms.

From a translational perspective, these findings herald a significant step toward the first-in-human applications of dual-organ gene editing therapies. The researchers underscored safety evaluations showing minimal immunogenic responses and off-target editing, further supporting clinical translation. This work also lays foundational principles for expanding the Dual SORT LNP approach to other multi-organ genetic diseases beyond AATD, potentially reshaping treatment paradigms.

The innovation here extends beyond technological novelty; it signifies a conceptual leap in how we envision and execute genetic medicine. By bridging genome editing with multi-organ delivery, this strategy confronts the inherent complexity of systemic diseases, transforming them from untreatable ailments into manageable or curable conditions. The coupling of molecular precision with targeted delivery exemplifies the convergence of synthetic biology, pharmacology, and nanotechnology.

Looking ahead, optimization of Dual SORT LNPs could include tailoring for additional tissues, scaling manufacturing processes, and integrating next-generation base editors with improved fidelity and editing scope. Moreover, combining this platform with advanced diagnostics may enable patient stratification and individualized dosing, harnessing the full potential of precision medicine.

In conclusion, the Dual SORT lipid nanoparticle system represents a landmark achievement in the field of gene therapy and precision genome editing. By overcoming the formidable challenge of delivering molecular editors to multiple, distinct organs, this technology offers a tangible pathway toward durable cures for complex genetic conditions such as Alpha-1 antitrypsin deficiency. As the landscape of therapeutic genome editing continues to evolve rapidly, approaches like these promise to redefine the boundaries of biomedical intervention, offering hope to millions affected by multisystemic genetic diseases.

Subject of Research: Alpha-1 antitrypsin deficiency and base editing delivery systems.

Article Title: Dual SORT LNPs for multi-organ base editing.

Article References:
Kim, M., Song, E.S., Chen, J.C. et al. Dual SORT LNPs for multi-organ base editing. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02675-z

Image Credits: AI Generated

Tags: Alpha-1 antitrypsin deficiencyDual SORT lipid nanoparticlesemphysema treatment strategiesgenetic diseases treatmentgenetic medicine delivery challenges.hepatocyte cellular damageinnovative therapeutic approacheslipid nanoparticle delivery systemliver and lung therapymulti-organ base editingprecise gene editing technologySERPINA1 gene mutations